OncoMed is having a no good, very bad week

In the space of one week, OncoMed Pharmaceuticals Inc. has been buffeted by not one, not two, but four pieces of bad news.

The latest negative results for the Redwood City, Ca.-based biotech OMED, -17.15% concern two drugs, intended for small cell lung cancer and colorectal cancer.

The former treatment missed both primary and secondary endpoints in a mid-stage clinical trial for small cell lung cancer. And the latter is having an early-stage clinical trial discontinued because the patient population couldn’t tolerate the combination, the company said Monday.

Read: OncoMed stock drops 25% after lung cancer drug misses in mid-stage clinical trial

>>> Original Source <<<